The goal of this clinical research study is to find out if combining a standard blood test (CA-125) that checks for ovarian cancer with other blood tests that check for related tumor markers may be helpful in the early detection of ovarian cancer in women who are at low risk. Tumor markers are substances in the blood that may be related to ovarian cancer.
Female, >/= 50 years old or less than 75 years old.
Postmenopausal (>/= 12 months amenorrhea).
Have at least one ovary.
Cancer-free and have not received any chemotherapy or radiation therapy for >/=12 months prior to enrolling on this study.
Female: Less than 50 years old or older than 75 years at the time of enrollment.
Psychiatric or psychological or other conditions which prevent a fully informed consent.
Prior removal of both ovaries.
Active non-ovarian malignancy.
Single group
Questionnaire
BehavioralQuestionnaires completed at baseline and during each follow up visit.
Rate of increase in CA 125 levels and other tumor markers over time
\[Time Frame: Based on CA-125 level and other tumor markers, 3 options will result: 1) re-draw blood (CA-125 and other tumor markers) in 1 year, 2) re-draw blood (CA-125 and other tumor markers) in 3 months, or 3) re-draw blood (CA-125 and other tumor markers) and TVUS in 6 weeks +/- 2 weeks.\]
Click on the lead sponsor to view all of their trials.
M.D. Anderson Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Golfers Against Cancer
Collaborator
